Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 12645517)

Published in J Biol Chem on March 14, 2003

Authors

Michael B Boffa1, Jeffrey D Hamill, Deborah Maret, Darryl Brown, Michelle L Scott, Michael E Nesheim, Marlys L Koschinsky

Author Affiliations

1: Department of Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada.

Articles by these authors

Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29

A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47

Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74

Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med (2012) 1.44

Solulin increases clot stability in whole blood from humans and dogs with hemophilia. Blood (2012) 1.44

Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem (2004) 1.21

Interplay between Rab35 and Arf6 controls cargo recycling to coordinate cell adhesion and migration. J Cell Sci (2012) 1.19

Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis (2007) 1.18

The factor V activation paradox. J Biol Chem (2004) 1.16

Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12

Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med (2006) 1.12

Further evidence for two functional forms of prothrombinase each specific for either of the two prothrombin activation cleavages. J Biol Chem (2007) 1.09

Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process. J Biol Chem (2002) 1.08

Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol (2012) 1.06

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res (2013) 1.04

Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2. J Cell Sci (2003) 1.01

Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem (2006) 1.00

Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem (2003) 0.99

Incorporation of factor Va into prothrombinase is required for coordinated cleavage of prothrombin by factor Xa. J Biol Chem (2005) 0.98

Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol (2003) 0.96

Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood (2007) 0.94

The structural integrity of anion binding exosite I of thrombin is required and sufficient for timely cleavage and activation of factor V and factor VIII. J Biol Chem (2006) 0.93

A control switch for prothrombinase: characterization of a hirudin-like pentapeptide from the COOH terminus of factor Va heavy chain that regulates the rate and pathway for prothrombin activation. J Biol Chem (2006) 0.92

Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91

A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J Biol Chem (2002) 0.90

The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase. Thromb Haemost (2008) 0.89

Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. J Lipid Res (2008) 0.89

An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem (2007) 0.88

Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry (2006) 0.87

The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem (2003) 0.87

A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med (2002) 0.87

Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol (2008) 0.86

Haemophilus somnus possesses two systems for acquisition of transferrin-bound iron. J Bacteriol (2004) 0.84

NF-κB-dependent role for cold-inducible RNA binding protein in regulating interleukin 1β. PLoS One (2013) 0.84

Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly. J Biol Chem (2003) 0.83

Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance. Biochemistry (2004) 0.83

Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem (2008) 0.83

The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis (2009) 0.82

Isolation and characterization of cotiaractivase, a novel low molecular weight prothrombin activator from the venom of Bothrops cotiara. Biochim Biophys Acta (2006) 0.82

Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3. Biochem J (2009) 0.82

Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem (2004) 0.82

Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays. Mol Pharmacol (2010) 0.81

Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10. Biochemistry (2005) 0.81

Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep (2013) 0.81

A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem (2004) 0.81

Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites. J Biol Chem (2011) 0.81

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res (2014) 0.80

The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. Biochim Biophys Acta (2005) 0.80

Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation. Biochemistry (2004) 0.79

The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific. Neoplasia (2007) 0.79

The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. J Biol Chem (2008) 0.79

Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein. Thromb Haemost (2004) 0.79

Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system. PLoS One (2013) 0.78

A novel cis-acting element from the 3'UTR of DNA damage-binding protein 2 mRNA links transcriptional and post-transcriptional regulation of gene expression. Nucleic Acids Res (2013) 0.78

A revisit of the two-form kinetic model of prothrombinase: A rebuttal. Biophys Chem (2011) 0.78

Nuclear magnetic resonance (NMR) solution structure, dynamics, and binding properties of the kringle IV type 8 module of apolipoprotein(a). Biochemistry (2007) 0.78

Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms. Int J Biochem Cell Biol (2013) 0.78

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD. J Crohns Colitis (2011) 0.78

A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation. J Biol Chem (2003) 0.78

Plasminogen binds to plasmin-modulated factor Xa by Ca(2+) - and C-terminal lysine-dependent and -independent interactions. Thromb Haemost (2007) 0.78

Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int (2002) 0.77

Screening for and management of elevated Lp(a). Curr Cardiol Rep (2013) 0.77

The fps/fes proto-oncogene regulates hematopoietic lineage output. Exp Hematol (2003) 0.77

Characterization of the caleosin gene family in the Triticeae. BMC Genomics (2014) 0.77

Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone. Blood Coagul Fibrinolysis (2013) 0.76

Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a). Mol Biol Cell (2012) 0.76

Down regulation of prothrombinase by activated protein C during prothrombin activation. Thromb Haemost (2010) 0.76

Differences in prethrombin-1 activation with human or bovine factor Va can be attributed to the heavy chain. Thromb Haemost (2009) 0.76

Comparative analyses of the lysine binding site properties of apolipoprotein(a) kringle IV types 7 and 10. Biochemistry (2002) 0.75

The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity. Thromb Haemost (2013) 0.75

Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis. J Thromb Thrombolysis (2012) 0.75

Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter. Br J Haematol (2007) 0.75

Gene expression analysis in the roots of salt-stressed wheat and the cytogenetic derivatives of wheat combined with the salt-tolerant wheatgrass, Lophopyrum elongatum. Plant Cell Rep (2013) 0.75

Identification of a novel apolipoprotein(a)-related protein from the European hedgehog (Erinaceus europaeus). DNA Seq (2003) 0.75

A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation. Arch Biochem Biophys (2003) 0.75

Regulation of the mouse gene encoding TAFI by TNFα: role of NFκB binding site. Cytokine (2012) 0.75

Activated protein C resistance and low molecular weight lipoprotein (a): dual pathogens for atherothrombosis? Thromb Res (2005) 0.75

An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol (2005) 0.75